Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | F13A1 | P00488 | 1/20 | 0.58 |
| ▸ | TGM1 | P22735 | 1/20 | 0.58 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | MYOC | Q99972 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10069262 | 0.91 | TGM2 (0.82) | TGM2MEN1KMT2ALMNAF13A1 | |
| SCHEMBL10012491 | 0.84 | TGM2 (0.70) | TGM2MEN1KMT2ALMNAF13A1 | |
| SCHEMBL30448387 | 0.84 | TGM2 (0.72) | TGM2MEN1KMT2ALMNARAB9A | |
| SCHEMBL10414259 | 0.83 | TGM2 (0.71) | TGM2MEN1KMT2ALMNANPC1 | |
| SCHEMBL439369 | 0.82 | TGM2 (0.79) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL5149342 | 0.80 | KMT2A (0.69) | TGM2MEN1KMT2ANPC1MAPT | |
| SCHEMBL6631700 | 0.79 | KMT2A (0.71) | TGM2MEN1KMT2ALMNARAB9A | |
| SCHEMBL4588400 | 0.79 | KMT2A (0.71) | TGM2MEN1KMT2ALMNARAB9A | |
| SCHEMBL9351738 | 0.79 | ALDH1A1 (0.72) | TGM2MEN1KMT2ALMNARAB9A | |
| SCHEMBL31596017 | 0.79 | TGM2 (0.66) | TGM2MEN1KMT2ALMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250389633-A1 | SYNTHETIC HUMAN CELL MIMIC PARTICLE FOR CYTOMETRIC OR COULTER DEVICE | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-12-25 | — | — | US | claimed |
| US-20250298042-A1 | ENGINEERED PARTICLES AS RED BLOOD CELL MIMICS AND COMPOSITIONS CONTAINING SAME FOR HEMATOLOGY | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-09-25 | — | — | US | claimed |
| EP-4608872-A2 | SIZE-TUNABLE SYNTHETIC PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME FOR IMMUNE CELL ACTIVATION | Slingshot Biosciences, Inc. (US) | 2025-09-03 | — | — | EP | claimed |
| US-12379387-B2 | Engineered particles as red blood cell mimics and compositions containing same for hematology | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-08-05 | — | — | US | claimed |
| EP-3256850-B1 | HYDROGEL PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME | SLINGSHOT BIOSCIENCES INC (US) | 2025-07-09 | — | — | EP | claimed |
| US-12352679-B2 | Synthetic human cell mimic particle for cytometric or coulter device | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-07-08 | — | — | US | claimed |
| EP-4577823-A2 | COMPOSITIONS AND METHODS FOR SINGLE WELL MULTIPLEXED CALIBRATION AND COMPENSATION | Slingshot Biosciences, Inc. (US) | 2025-07-02 | — | — | EP | claimed |
| US-20250189428-A1 | COMPOSITIONS AND METHODS FOR SINGLE WELL MULTIPLEXED CALIBRATION AND COMPENSATION | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-06-12 | — | — | US | claimed |
| US-12312595-B2 | Hydrogel particles as feeder cells and as synthetic antigen presenting cells | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-05-27 | — | — | US | claimed |
| US-20250164373-A1 | SYNTHETIC HUMAN CELL MIMIC PARTICLE FOR CYTOMETRIC OR COULTER DEVICE | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-05-22 | — | — | US | claimed |
| US-6673886-B2 | FOR INTRAOCULAR LENSES | BAUSCH & LOMB INCORPORATED | 2004-01-06 | — | — | US | claimed |
| US-6657030-B2 | High refractive index and hydrophilic monomers, a crosslinker, an initiator and water | BAUSCH & LOMB INCORPORATED | 2003-12-02 | — | — | US | claimed |
| US-6657029-B2 | High refractive index monomer, greater amount of a hydrophilic monomer, crosslinker, and initiator; give water content; intraocular lenses | BAUSCH & LOMB INCORPORATED | 2003-12-02 | — | — | US | claimed |
| US-6555711-B1 | Reacting an N-allylimino nitrobenzene compound with a diamino-dinucleophile to form an alpha-amino-N- allylamidino-nitrobenzene compound; chemical intermediate for a pyrazolo(1,5-b)(1,2,4)triazole color photographic coupler | EASTMAN KODAK COMPANY | 2003-04-29 | — | — | US | claimed |
| US-20020049290-A1 | High refractive index hydrogel compositions for ophthalmic implants | VANDERBILT DAVID P (US) | 2002-04-25 | — | — | US | claimed |
| US-20020042483-A1 | High refractive index hydrogel compositions for ophthalmic implants | VANDERBILT DAVID P (US) | 2002-04-11 | — | — | US | claimed |
| US-20020042484-A1 | High refractive index hydrogel compositions for ophthalmic implants | BAUSCH & LOMB MEXICO, S.A. DE C.V. (MX) | 2002-04-11 | — | — | US | claimed |
| US-20020037984-A1 | High refractive index hydrogel compositions for ophthalmic implants | VANDERBILT DAVID P (US) | 2002-03-28 | — | — | US | claimed |
| US-6329485-B1 | FOR INTRAOCULAR LENSES | BAUSCH & LOMB INCORPORATED | 2001-12-11 | — | — | US | claimed |
| WO-2000034804-A1 | HIGH REFRACTIVE INDEX HYDROGEL COMPOSITIONS FOR OPHTHALMIC IMPLANTS | BAUSCH & LOMB SURGICAL, INC. (US) | 2000-06-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250389633-A1 | SYNTHETIC HUMAN CELL MIMIC PARTICLE FOR CYTOMETRIC OR COULTER DEVICE | CD4, ICOS, CD69 | TGM2 1495/4885MEN1 3203/4885KMT2A 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.